PE20231940A1 - Compuestos a base de indazol y metodos de uso asociados - Google Patents

Compuestos a base de indazol y metodos de uso asociados

Info

Publication number
PE20231940A1
PE20231940A1 PE2023002653A PE2023002653A PE20231940A1 PE 20231940 A1 PE20231940 A1 PE 20231940A1 PE 2023002653 A PE2023002653 A PE 2023002653A PE 2023002653 A PE2023002653 A PE 2023002653A PE 20231940 A1 PE20231940 A1 PE 20231940A1
Authority
PE
Peru
Prior art keywords
ptm
clm
compounds
optionally substituted
useful
Prior art date
Application number
PE2023002653A
Other languages
English (en)
Inventor
Erika Araujo
Michael Berlin
Steven M Sparks
Jing Wang
Wei Zhang
Hanqing Dong
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of PE20231940A1 publication Critical patent/PE20231940A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a un compuesto heterobifuncional que tiene la estructura quimica: PTM-L-CLM, en donde: a) CLM tiene la estructura quimica a1, a2, a3 o a4, donde: W es CH2, C=O, SO2 o NH; cada X y Z esta ausente o es O u S; G y A son H o alquilo lineal o ramificado opcionalmente sustituido; cada Q1 a Q4 son N, CH o CR; n es un numero entero de 1 a 10; R es un enlace, H, entre otros; b) PTM tiene la estructura PTM-IA, PTM-IIIA1, PTM-IIIA2, PTM-IIIA3 o PTMIIIA4, en donde: R1 es isopropilo, terc-butilo, entre otros; R2 es hidrogeno, F, Cl, OH, entre otros; X6, X7 y X8 son cada uno CH o N; X1 a X5 son cada uno N o CH opcionalmente sustituido con R2 cuando CH; el anillo A es un cicloalquilo, heterocicloalquilo, bicicloalquilo, entre otros; las lineas punteadas indica el punto de union con la L; y c) L es un grupo enlazador quimico que acopla covalentemente la CLM a la PTM. Son compuestos especificos los compuestos 365, 367, entre otros. Tambien se refiere a una composicion farmaceutica. Los compuestos de la invencion son utiles como moduladores de la ubiquitinacion dirigida de la quinasa 2 repetida rica en leucina (LRRK2), siendo utiles en el tratamiento del parkinson, demencia de cuerpos lascivos, enfermedad de Crohn, lepra, neuroinflamacion, entre otros.
PE2023002653A 2021-03-19 2022-03-19 Compuestos a base de indazol y metodos de uso asociados PE20231940A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163163328P 2021-03-19 2021-03-19
US202163228731P 2021-08-03 2021-08-03
US202163243014P 2021-09-10 2021-09-10
US202163245411P 2021-09-17 2021-09-17
PCT/US2022/021049 WO2022198112A1 (en) 2021-03-19 2022-03-19 Indazole based compounds and associated methods of use

Publications (1)

Publication Number Publication Date
PE20231940A1 true PE20231940A1 (es) 2023-12-05

Family

ID=81308072

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002653A PE20231940A1 (es) 2021-03-19 2022-03-19 Compuestos a base de indazol y metodos de uso asociados

Country Status (14)

Country Link
US (1) US11981683B2 (es)
EP (1) EP4308557A1 (es)
JP (1) JP2024512501A (es)
KR (1) KR20230173234A (es)
AU (1) AU2022238476A1 (es)
BR (1) BR112023018973A2 (es)
CA (1) CA3211347A1 (es)
CO (1) CO2023013402A2 (es)
CR (1) CR20230449A (es)
DO (1) DOP2023000198A (es)
IL (1) IL305933A (es)
MX (1) MX2023011051A (es)
PE (1) PE20231940A1 (es)
WO (1) WO2022198112A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023066350A1 (zh) * 2021-10-22 2023-04-27 标新生物医药科技(上海)有限公司 Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
WO2023196720A2 (en) * 2022-04-04 2023-10-12 Brenig Therapeutics, Inc. Lrrk2 inhibitors
WO2024073475A1 (en) * 2022-09-27 2024-04-04 Oncopia Therapeutics, Inc. D/B/A Proteovant Therapeutics, Inc. Cereblon ligands and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736569A (zh) 2012-01-12 2015-06-24 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9718818B2 (en) 2013-08-22 2017-08-01 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
AU2015247817C1 (en) 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
AU2017341723B2 (en) * 2016-10-11 2021-12-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP2022504762A (ja) * 2018-10-16 2022-01-13 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Ｌｒｒｋ２の野生型および変異型の分解誘導剤
CA3172387A1 (en) * 2020-03-21 2021-09-30 Arvinas Operations, Inc. Indazole based compounds and associated methods of use
CA3200685A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use

Also Published As

Publication number Publication date
AU2022238476A1 (en) 2023-10-05
US11981683B2 (en) 2024-05-14
CR20230449A (es) 2023-11-23
BR112023018973A2 (pt) 2023-12-12
DOP2023000198A (es) 2024-01-31
EP4308557A1 (en) 2024-01-24
JP2024512501A (ja) 2024-03-19
US20230097358A1 (en) 2023-03-30
WO2022198112A1 (en) 2022-09-22
CO2023013402A2 (es) 2024-02-15
KR20230173234A (ko) 2023-12-26
MX2023011051A (es) 2023-09-28
IL305933A (en) 2023-11-01
CA3211347A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
PE20231940A1 (es) Compuestos a base de indazol y metodos de uso asociados
PE20210004A1 (es) Inhibidores de mcl-1
ECSP066475A (es) Derivados de tropano
DOP2003000624A (es) Derivados de tropano como moduladores de ccr5
CL2022000102A1 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos.
CR20120152A (es) Derivados de 3-aminopirrolidina como moduladores de receptores de quimocina
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
CL2020001817A1 (es) Moduladores del receptor c5a
UY26662A1 (es) Compuestos que contienen benzamido-piperidina y compuestos relacionados.
ES2085627T3 (es) Nuevos derivados de perhidroisoindol, su preparacion y las composiciones farmaceuticas que les contienen.
HUP9801887A2 (hu) CCR-3 receptor antagonista hatású gyűrűs aminszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények
HUP0301391A2 (hu) Piperazin- és piperidinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
SV2008002986A (es) Moduladores de indol sulfonamida de receptores de progesterona ref. x-17207
NO20071476L (no) Antidiuretiske midler.
PE20081227A1 (es) Derivados indazolil sulfonamidas como moduladores de glucocorticoides
ES2109190B1 (es) Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
MA41337A (fr) Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3
ECSP23044370A (es) Compuestos farmacéuticos
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
DE60208694D1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
AR044275A1 (es) Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias
DE60037888D1 (de) Piperazinderivate als aktivitätsmodulatoren der chemokinrezeptoren
DE69727305D1 (de) Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
PA8583801A1 (es) Piperazinas sustituidas heterocíclicas para el tratamiento de la esquizofrenia